- Home
- RPTX vs DTIL Comparison
RPTX vs DTIL Comparison
Compare RPTX & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPTX
- DTIL
- Stock Information
- Founded
- RPTX 2016
- DTIL 2006
- Country
- RPTX Canada
- DTIL United States
- Employees
- RPTX N/A
- DTIL N/A
- Industry
- RPTX Biotechnology: Pharmaceutical Preparations
- DTIL Biotechnology: Pharmaceutical Preparations
- Sector
- RPTX Health Care
- DTIL Health Care
- Exchange
- RPTX Nasdaq
- DTIL Nasdaq
- Market Cap
- RPTX 63.9M
- DTIL 51.6M
- IPO Year
- RPTX 2020
- DTIL 2019
- Fundamental
- Price
- RPTX $1.56
- DTIL $5.15
- Analyst Decision
- RPTX Strong Buy
- DTIL Strong Buy
- Analyst Count
- RPTX 3
- DTIL 2
- Target Price
- RPTX $4.50
- DTIL $47.00
- AVG Volume (30 Days)
- RPTX 717.8K
- DTIL 242.5K
- Earning Date
- RPTX 08-05-2025
- DTIL 08-04-2025
- Dividend Yield
- RPTX N/A
- DTIL N/A
- EPS Growth
- RPTX N/A
- DTIL N/A
- EPS
- RPTX N/A
- DTIL N/A
- Revenue
- RPTX $1,073,000.00
- DTIL $51,141,000.00
- Revenue This Year
- RPTX N/A
- DTIL N/A
- Revenue Next Year
- RPTX N/A
- DTIL $53.21
- P/E Ratio
- RPTX N/A
- DTIL N/A
- Revenue Growth
- RPTX N/A
- DTIL N/A
- 52 Week Low
- RPTX $0.89
- DTIL $3.61
- 52 Week High
- RPTX $4.22
- DTIL $11.09
- Technical
- Relative Strength Index (RSI)
- RPTX 58.19
- DTIL 62.43
- Support Level
- RPTX $1.37
- DTIL $4.51
- Resistance Level
- RPTX $1.68
- DTIL $5.25
- Average True Range (ATR)
- RPTX 0.08
- DTIL 0.32
- MACD
- RPTX 0.00
- DTIL 0.08
- Stochastic Oscillator
- RPTX 61.29
- DTIL 89.80
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.